Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Smallpox Vaccine Injury Compensation Program.

Paul T Clark1, Stan Levin

  • 1US Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, and Smallpox Vaccine Injury Compensation Program, Rockville, Maryland, USA.

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|March 20, 2008
PubMed
Summary
This summary is machine-generated.

The Smallpox Vaccine Injury Compensation Program was established in 2003 to cover medical costs and lost income for those injured by smallpox vaccines. As of 2006, 62 claims were filed, with 19 deemed eligible and 27 denied.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The optimal synapse for sparse, binary signals in the rod pathway.

Neural computationยท2005
Same journal

Reconsidering ambiguous language in infectious disease consult recommendations.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of Americaยท2026
Same journal

Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of Americaยท2026
Same journal

Larger Blood Volume Increases Detection of Fastidious Mycobacteria and Fungi in Blood Culture.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of Americaยท2026
Same journal

Anticalcitonin: Limited utility of a context-dependent biomarker demonstrated in another real-world data set.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of Americaยท2026
Same journal

Procalcitonin Testing in Community-Acquired Pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of Americaยท2026
Same journal

Wanted: A Relevant Correlate of Protection for Dengue Vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of Americaยท2026
See all related articles

Area of Science:

  • Public Health
  • Biosecurity
  • Vaccine Injury Compensation

Background:

  • In response to potential smallpox bioterrorism, the US Department of Health and Human Services (DHHS) recommended smallpox vaccination for certain personnel in 2003.
  • The Smallpox Emergency Personnel Protection Act of 2003 was enacted to address concerns regarding vaccine-related injuries.

Purpose of the Study:

  • To outline the establishment and function of the Smallpox Vaccine Injury Compensation Program.
  • To report on the initial claims and outcomes for individuals seeking compensation for smallpox vaccine injuries.

Main Methods:

  • The Smallpox Vaccine Injury Compensation Program was established by federal legislation.
  • Data collection involved tracking benefit requests, medical eligibility determinations, denials, and filing deadline adherence.

Main Results:

  • As of September 2006, 62 individuals had requested benefits under the program.
  • Of these, 19 were determined to be medically eligible for compensation.
  • Additionally, 27 claims were denied, and 16 requests were submitted after the statutory filing deadline.

Conclusions:

  • The Smallpox Vaccine Injury Compensation Program provides a safety net for individuals experiencing adverse events from smallpox vaccination.
  • The program's initial data indicates a significant number of claims, highlighting the importance of monitoring vaccine safety and compensation processes.